Login to Your Account

Other News To Note

Monday, July 1, 2013
• Vivus Inc., of Mountain View, Calif., responded to statements by First Manhattan Co. (FMC), a 9. 1 percent shareholder, alleging the launch of obesity drug Qsymia (phentermine/topiramate extended release) was mismanaged and Vivus did not adequately address out-of-pocket costs to patients and mismanaged the regulatory process for the drug, branded Qsiva, in the European Union.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription